Holen Sie sich die Stockscreener-App
6.75
8.00%
0.50
Handel nachbörslich:
6.60
-0.15
-2.22%
Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten
Day One Biopharmaceuticals Receives Bullish Ratings from Analysts Amid Promising Growth Prospects - AInvest
Day One Biopharmaceutical Stock Price, Quotes and Forecasts | NASDAQ:DAWN - Benzinga
Day One Biopharmaceuticals: Bear Case Priced In, But Bull Case Is Not (Rating Upgrade) - Seeking Alpha
Day One Biopharmaceuticals Maintains Buy Rating on Promising Growth and Strategic Innovation - AInvest
A Quick Look at Today's Ratings for Day One Biopharmaceuticals(DAWN.US), With a Forecast Between $16 to $26 - 富途牛牛
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q2 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $36 - 富途牛牛
Day One Biopharma’s Earnings Call Highlights Growth and Strategy - TipRanks
Promising Growth and Strategic Innovation Drive Buy Rating for Day One Biopharmaceuticals - TipRanks
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Day One Biopharmaceuticals Plunges 13.95% Despite Revenue Surge - AInvest
Day One Biopharmaceuticals shares fall 14.24% premarket after Q2 2025 earnings call. - AInvest
Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate - MSN
Day One Biopharmaceuticals (DAWN): A High-Growth Biotech Play in Pediatric Oncology with a Clear Path to Value Creation - AInvest
Day One Biopharmaceuticals Inc (DAWN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Day One Biopharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Day One Biopharma Reports Strong Q2 2025 Growth - TipRanks
Day One Biopharmaceuticals Reports Q2 2025 Financial Results and Strategic Appointments. - AInvest
Day One Biopharmaceuticals' Q2 2025: Unpacking Contradictions in Treatment Durability, Financial Projections, and Growth Trajectory - AInvest
Day One Biopharmaceuticals: Scaling OJEMDA Revenue While Strengthening R&D and Financial Discipline - AInvest
Transcript : Day One Biopharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Day One Biopharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Day One Biopharma Q2 2025 revenue growth impresses - Investing.com Canada
Earnings call transcript: Day One Biopharma Q2 2025 revenue growth impresses By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Day One Biopharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Day One Biopharmaceuticals reports Q2 EPS (29c), consensus (34c) - TipRanks
Day One Biopharmaceuticals Q2 Revenue Rises Amid Leadership Changes and Earnings Calls - AInvest
Day One Biopharmaceuticals Q2 OJEMDA revenue rises - MarketScreener
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress - The Manila Times
Day One Biopharmaceuticals Reports Q2 2025 Financial Results, Expects $140-150M in OJEMDA Net Product Revenue for FY25 - AInvest
What are analysts’ price targets for Day One Biopharmaceuticals Inc. in the next 12 monthsFree Stock Selection - Jammu Links News
How volatile is Day One Biopharmaceuticals Inc. stock compared to the marketDiscover hidden gems in the stock market - Jammu Links News
What is the risk reward ratio of investing in Day One Biopharmaceuticals Inc. stock - Jammu Links News
Is it the right time to buy Day One Biopharmaceuticals Inc. stockCapitalize on high-yield stock opportunities - Jammu Links News
Day One Biopharmaceuticals Inc. Stock Analysis and ForecastCapitalize on emerging trends for profits - Jammu Links News
Why is Day One Biopharmaceuticals Inc. stock attracting strong analyst attentionFree Investment Community - Jammu Links News
How does Day One Biopharmaceuticals Inc. generate profit in a changing economyTremendous growth opportunities - Jammu Links News
Is Day One Biopharmaceuticals Inc. a growth stock or a value stockBuild a portfolio that withstands market volatility - Jammu Links News
How many analysts rate Day One Biopharmaceuticals Inc. as a “Buy”Unbelievable profit margins - Jammu Links News
What are the technical indicators suggesting about Day One Biopharmaceuticals Inc.Build a portfolio that outperforms consistently - Jammu Links News
Does Day One Biopharmaceuticals Inc. stock perform well during market downturnsPhenomenal trading returns - Jammu Links News
How strong is Day One Biopharmaceuticals Inc. company’s balance sheetInvest smarter with cutting-edge analytics - Jammu Links News
What makes Day One Biopharmaceuticals Inc. stock price move sharplyInvest smarter with daily market updates - Jammu Links News
Day One Biopharmaceuticals Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Can a trend reversal in Day One Biopharmaceuticals Inc. lead to recoveryYield Curve Outlook and Long-Term Implication Summary - Newser
Day One Biopharmaceuticals Inc. stock chart pattern explainedRisk/Reward Optimization Entry Point Analysis - Newser
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 - 富途牛牛
Published on: 2025-07-30 22:40:17 - Newser
Can Day One Biopharmaceuticals Inc. recover in the next quarterWeekly Stock Opportunity Radar Scanner Activated - metal.it
How Day One Biopharmaceuticals Inc. stock performs during market volatilityNeural Model for Stock Price Movement - Newser
Published on: 2025-07-30 04:25:27 - Newser
Trapped Investors in Day One Biopharmaceuticals Inc. Await Breakout SignalMulti-Bagger Potential Stock Forecast Tools Released - beatles.ru
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):